Stratify Genomics develops genetic testing to assess cancer risk for the general population using proprietary chemistry and low-cost next-generation sequencing. It launched its flagship Prompt Prostate Genetic Score (PGS) last year, which provides lifetime risk assessment for prostate cancer and includes decision tools to recommend screening frequency. The company was founded by Dr. Karim Kader, head of Urologic Oncology at UC San Diego, and is led by President Martyn Gross. Stratify says its technology aims to save lives and reduce healthcare spending by enabling modified screening frequency based on genetic risk. The business was initially founded and funded by oncologists with the purpose of preventing cancer at scale. The company recently raised $2.2M in a third seed round and will use the proceeds to accelerate sales and commercial partnerships.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2019